指南与共识食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

幽门螺杆菌感染的管理:Maastricht VI/Florence 共识报告

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report.
指南 / 共识 · Gut · 2022-08-11

幽门螺杆菌感染已被正式认定为感染性疾病并纳入ICD-11,据此原则上建议所有感染者均应接受治疗。本共识由29个国家41位专家分五个工作组(适应证/关联、诊断、治疗、预防/胃癌、幽门螺杆菌与肠道菌群)评估新数据并经全体投票形成推荐,涵盖临床情景识别、检测、耐药背景下的治疗选择及胃癌预防等。

要点

  • 幽门螺杆菌感染为感染性疾病,原则上建议所有感染者接受治疗。
  • 治疗受抗生素耐药持续上升挑战,需考虑药敏检测与分子技术并审慎选择初治与补救方案。
  • 共识覆盖适应证、诊断、治疗、胃癌预防及肠道菌群五方面并形成推荐。

核心结论

  • 幽门螺杆菌感染被正式认定为感染性疾病并纳入ICD-11,原则上建议所有感染者接受治疗。
  • 针对幽门螺杆菌胃炎相关广泛临床谱中的具体问题需定期更新以优化管理。
  • 共识就不同临床情景的识别、规范检测及预防胃癌和其他并发症的有效策略给出推荐。

研究设计与样本

  • Maastricht VI/Florence 2021共识报告由来自29个国家的41位专家参与制定。
  • 专家分五个工作组评估幽门螺杆菌感染相关新数据:适应证/关联、诊断、治疗、预防/胃癌、幽门螺杆菌与肠道菌群。
  • 各工作组结果提交全体参与者进行最终共识投票,推荐基于最佳可得证据及与各临床领域管理的相关性。

主要发现

  • 幽门螺杆菌治疗面临抗生素耐药持续上升的挑战,需要药敏检测并考虑新型分子技术。
  • 需审慎选择一线和补救治疗。
  • 共识还考虑了幽门螺杆菌及抗生素治疗对肠道菌群的作用与影响。

关键数值与推荐

  • 幽门螺杆菌感染为感染性疾病,原则上建议所有感染者接受治疗。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Helicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management.The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered.Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. PMID: 35944925. doi:10.1136/gutjnl-2022-327745

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。